Glycosylation Gene Signatures as Prognostic Biomarkers in Glioblastoma
Tong Zhao
Department of Neurosurgery, Neurosurgery Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Department of Neurosurgery, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fuzhou, China
Clinical Research and Translation Center, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Search for more papers by this authorHongliang Ge
Department of Neurosurgery, Neurosurgery Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Department of Neurosurgery, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fuzhou, China
Clinical Research and Translation Center, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Search for more papers by this authorChenchao Lin
Department of Neurosurgery, Neurosurgery Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Department of Neurosurgery, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fuzhou, China
Clinical Research and Translation Center, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Search for more papers by this authorCorresponding Author
Xiyue Wu
Department of Neurosurgery, Neurosurgery Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Department of Neurosurgery, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fuzhou, China
Clinical Research and Translation Center, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Correspondence:
Jianwu Chen ([email protected])
Xiyue Wu ([email protected])
Search for more papers by this authorCorresponding Author
Jianwu Chen
Department of Neurosurgery, Neurosurgery Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Department of Neurosurgery, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fuzhou, China
Clinical Research and Translation Center, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Correspondence:
Jianwu Chen ([email protected])
Xiyue Wu ([email protected])
Search for more papers by this authorTong Zhao
Department of Neurosurgery, Neurosurgery Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Department of Neurosurgery, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fuzhou, China
Clinical Research and Translation Center, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Search for more papers by this authorHongliang Ge
Department of Neurosurgery, Neurosurgery Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Department of Neurosurgery, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fuzhou, China
Clinical Research and Translation Center, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Search for more papers by this authorChenchao Lin
Department of Neurosurgery, Neurosurgery Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Department of Neurosurgery, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fuzhou, China
Clinical Research and Translation Center, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Search for more papers by this authorCorresponding Author
Xiyue Wu
Department of Neurosurgery, Neurosurgery Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Department of Neurosurgery, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fuzhou, China
Clinical Research and Translation Center, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Correspondence:
Jianwu Chen ([email protected])
Xiyue Wu ([email protected])
Search for more papers by this authorCorresponding Author
Jianwu Chen
Department of Neurosurgery, Neurosurgery Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Department of Neurosurgery, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fuzhou, China
Clinical Research and Translation Center, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Correspondence:
Jianwu Chen ([email protected])
Xiyue Wu ([email protected])
Search for more papers by this authorFunding: This work was supported by National Natural Science Foundation of China: 82301543. Joint Funds for the Innovation of Science and Technology, Fujian Province: 2024Y9123, Fujian Provincial science and Technology Innovation joint Fund Project: 2021Y9149, Leading Project Foundation of Science and Technology, Fujian Province: 2021Y0013.
Tong Zhao, Hongliang Ge, and Chenchao Lin are regarded as co-first authors.
ABSTRACT
Objective
Glioblastoma (GBM) is an aggressive brain tumor characterized by significant heterogeneity. This study investigates the role of glycosylation-related genes in GBM subtyping, prognosis, and response to therapy.
Methods
We analyzed mRNA expression data and clinical information from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Glycosylation-related genes were selected for differential expression analysis, sample clustering, and survival analysis. Immune cell infiltration and drug sensitivity were evaluated using CIBERSORT and oncoPredict, respectively. A prognostic model was constructed with Lasso regression.
Results
GBM samples were stratified into two glycosylation-related subtypes, showing distinct survival outcomes, with higher glycosylation expression correlating with poorer prognosis. Immune microenvironment analysis revealed differences in T-cell infiltration and immune checkpoint expression between subtypes, indicating variable immunotherapy responses. The prognostic model based on glycosylation genes demonstrated significant predictive value for patient survival.
Conclusion
Glycosylation-related gene expression contributes to GBM heterogeneity and is a valuable biomarker for prognosis and treatment stratification. This study provides insights into personalized treatment approaches for GBM based on glycosylation-related molecular subtypes.
Conflicts of Interest
The authors declare no conflicts of interest.
Open Research
Data Availability Statement
This study includes (1) public mRNA and clinical data from TCGA (https://portal.gdc.cancer.gov/) and GEO (https://www.ncbi.nlm.nih.gov/gds/); and (2) experimental data from cell assays and in vivo glioma models, available from the corresponding author upon request.
Supporting Information
| Filename | Description |
|---|---|
| acn370068-sup-0001-FigureS1.tifTIFF image, 4.2 MB |
Figure S1. |
| acn370068-sup-0002-FigureS2.tifTIFF image, 8.7 MB |
Figure S2. |
| acn370068-sup-0003-FigureS3.tifTIFF image, 3.2 MB |
Figure S3. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1H. Wu, C. Guo, C. Wang, et al., “Single-Cell RNA Sequencing Reveals Tumor Heterogeneity, Microenvironment, and Drug-Resistance Mechanisms of Recurrent Glioblastoma,” Cancer Science 114, no. 6 (2023): 2609–2621, https://doi.org/10.1111/cas.15773.
- 2S. J. Coniglio, “Macrophages in the Glioblastoma Tumor Microenvironment,” IJMS 24, no. 10 (2023): 8978, https://doi.org/10.3390/ijms24108978.
10.3390/ijms24108978 Google Scholar
- 3J. Ma, C. C. Chen, and M. Li, “Macrophages/Microglia in the Glioblastoma Tumor Microenvironment,” IJMS 22, no. 11 (2021): 5775, https://doi.org/10.3390/ijms22115775.
- 4M. J. Zorman, P. Webb, M. Nixon, et al., “Surgical and Oncological Score to Estimate the Survival Benefit of Resection and Chemoradiotherapy in Elderly (≥ 70 Years) Glioblastoma Patients: A Preliminary Analysis,” Neuro-Oncology Advances 4, no. 1 (2022): vdac007, https://doi.org/10.1093/noajnl/vdac007.
- 5R. Altieri, F. Certo, D. Pacella, et al., “Metabolic Delineation of IDH1 Wild-Type Glioblastoma Surgical Anatomy: How to Plan the Tumor Extent of Resection,” Journal of Neuro-Oncology 162, no. 2 (2023): 417–423, https://doi.org/10.1007/s11060-023-04305-7.
- 6C. I. Tsien, S. L. Pugh, A. P. Dicker, et al., “NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma,” JCO 41, no. 6 (2023): 1285–1295, https://doi.org/10.1200/jco.22.00164.
- 7Y. Zou, X. Sun, Q. Yang, et al., “Blood-Brain Barrier–Penetrating Single CRISPR-Cas9 Nanocapsules for Effective and Safe Glioblastoma Gene Therapy,” Science Advances 8, no. 16 (2022): eabm8011, https://doi.org/10.1126/sciadv.abm8011.
- 8J. F. Shern, J. Selfe, E. Izquierdo, et al., “Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium,” JCO 39, no. 26 (2021): 2859–2871, https://doi.org/10.1200/jco.20.03060.
- 9S. Li, L. Dong, Z. Pan, and G. Yang, “Targeting the Neural Stem Cells in Subventricular Zone for the Treatment of Glioblastoma: An Update From Preclinical Evidence to Clinical Interventions,” Stem Cell Research & Therapy 14, no. 1 (2023): 125, https://doi.org/10.1186/s13287-023-03325-4.
- 10M. A. Azab, S. Ghozy, S. F. Hassanein, and A. Y. Azzam, “Specific Preoperative Dynamic Contrast-Enhanced MRI Semi-Quantitative Markers Can Correlate With Vascularity in Specific Areas of Glioblastoma Tissue and Predict Recurrence,” Cureus 13, no. 6 (2021): e15528, https://doi.org/10.7759/cureus.15528.
- 11V. Di Nunno, E. Franceschi, A. Tosoni, L. Gatto, S. Bartolini, and A. A. Brandes, “Glioblastoma Microenvironment: From an Inviolable Defense to a Therapeutic Chance,” Frontiers in Oncology 12, no. 12 (2022): 852950, https://doi.org/10.3389/fonc.2022.852950.
- 12S. J. Derby, L. Dutton, K. E. Strathdee, et al., “Inhibition of ATR Opposes Glioblastoma Invasion Through Disruption of Cytoskeletal Networks and Integrin Internalization via Macropinocytosis,” Neuro-Oncology 26, no. 4 (2023): 625–639, https://doi.org/10.1093/neuonc/noad210.
- 13K. Torres-Obreque, E. K. Kleingesinds, J. H. P. M. Santos, et al., “PEGylation Versus Glycosylation: Effect on the Thermodynamics and Thermostability of Crisantaspase,” Preparative Biochemistry & Biotechnology 54, no. 4 (2023): 503–513, https://doi.org/10.1080/10826068.2023.2249100.
- 14M. Plays, S. Müller, and R. Rodriguez, “Chemistry and Biology of Ferritin,” Metallomics 13, no. 5 (2021): mfab021, https://doi.org/10.1093/mtomcs/mfab021.
- 15L. Zhao, S. Cheng, L. Fan, B. Zhang, and S. Xu, “TIM-3: An Update on Immunotherapy,” International Immunopharmacology 99 (2021): 107933, https://doi.org/10.1016/j.intimp.2021.107933.
- 16M. A. Stanczak, N. Rodrigues Mantuano, N. Kirchhammer, et al., “Targeting Cancer Glycosylation Repolarizes Tumor-Associated Macrophages Allowing Effective Immune Checkpoint Blockade,” Science Translational Medicine 14, no. 669 (2022): eabj1270, https://doi.org/10.1126/scitranslmed.abj1270.
- 17S. Qi, L. Su, J. Li, et al., “Arf6-Driven Endocytic Recycling of CD147 Determines HCC Malignant Phenotypes,” Journal of Experimental & Clinical Cancer Research 38, no. 1 (2019): 471, https://doi.org/10.1186/s13046-019-1464-9.
- 18S. Qi, L. Su, J. Li, et al., “YIPF2 Is a Novel Rab-GDF That Enhances HCC Malignant Phenotypes by Facilitating CD147 Endocytic Recycle,” Cell Death & Disease 10, no. 6 (2019): 462, https://doi.org/10.1038/s41419-019-1709-8.
- 19B. Ô. Perez Gonçalves, G. S. P. dos Santos, W. P. de Andrade, S. L. Fialho, D. A. Gomes, and L. M. Silva, “Phenotypic Changes on Central Nervous System (CNS) Tumor Cell Lines Cultured In Vitro 2D and 3D Models and Treated With Cisplatin,” Acta Histochemica 123, no. 6 (2021): 151768, https://doi.org/10.1016/j.acthis.2021.151768.
- 20M. Billerhart, M. Hunjadi, V. Hawlin, et al., “Recombinant Human CD19 in CHO-K1 Cells: Glycosylation Patterns as a Quality Attribute of High Yield Processes,” IJMS 24, no. 13 (2023): 10891, https://doi.org/10.3390/ijms241310891.
- 21T. Kissel, R. E. M. Toes, T. W. J. Huizinga, and M. Wuhrer, “Glycobiology of Rheumatic Diseases,” Nature Reviews Rheumatology 19, no. 1 (2022): 28–43, https://doi.org/10.1038/s41584-022-00867-4.
- 22S. Huo, Q. Wang, W. Shi, et al., “ATF3/SPI1/SLC31A1 Signaling Promotes Cuproptosis Induced by Advanced Glycosylation End Products in Diabetic Myocardial Injury,” IJMS 24, no. 2 (2023): 1667, https://doi.org/10.3390/ijms24021667.
- 23B. Radovani and I. Gudelj, “N-Glycosylation and Inflammation; the Not-So-Sweet Relation,” Frontiers in Immunology 13 (2022): 893365, https://doi.org/10.3389/fimmu.2022.893365.
- 24V. Krishnamoorthy, J. Daly, and S. Wisnovsky, “Identifying Genetic Regulators of Protein-Glycan Interactions With Genome-Wide CRISPR Screening,” Current Protocols 3, no. 1 (2023): e646, https://doi.org/10.1002/cpz1.646.
- 25Y. Bao, J. Zhai, H. Chen, et al., “Targeting m6A Reader YTHDF1 Augments Antitumour Immunity and Boosts Anti-PD-1 Efficacy in Colorectal Cancer,” Gut 72, no. 8 (2023): 1497–1509, https://doi.org/10.1136/gutjnl-2022-328845.
- 26C. Zhu, X. Chen, T. Q. Liu, et al., “Hexosaminidase B-Driven Cancer Cell-Macrophage Co-Dependency Promotes Glycolysis Addiction and Tumorigenesis in Glioblastoma,” Nature Communications 15, no. 1 (2024): 8506, https://doi.org/10.1038/s41467-024-52888-0.
- 27X. Cai, R. G. Briggs, H. B. Homburg, et al., “Application of Microfluidic Devices for Glioblastoma Study: Current Status and Future Directions,” Biomedical Microdevices 22, no. 3 (2020): 60, https://doi.org/10.1007/s10544-020-00516-1.
- 28D. K. Tripathy, L. P. Panda, S. Biswal, and K. Barhwal, “Insights Into the Glioblastoma Tumor Microenvironment: Current and Emerging Therapeutic Approaches,” Frontiers in Pharmacology 15 (2024): 1355242, https://doi.org/10.3389/fphar.2024.1355242.
- 29E. Martell, H. Kuzmychova, H. Senthil, et al., “Compensatory Cross-Talk Between Autophagy and Glycolysis Regulates Senescence and Stemness in Heterogeneous Glioblastoma Tumor Subpopulations,” Acta Neuropathologica Communications 11, no. 1 (2023): 110, https://doi.org/10.1186/s40478-023-01604-y.
- 30H. Liu, L. Zhang, Y. Tan, Y. Jiang, and H. Lu, “Observation of the Delineation of the Target Volume of Radiotherapy in Adult-Type Diffuse Gliomas After Temozolomide-Based Chemoradiotherapy: Analysis of Recurrence Patterns and Predictive Factors,” Radiation Oncology 18, no. 1 (2023): 16, https://doi.org/10.1186/s13014-023-02203-w.
- 31Y. Wang, Y. Xie, L. Qian, et al., “RAB42 Overexpression Correlates With Poor Prognosis, Immune Cell Infiltration and Chemoresistance,” Frontiers in Pharmacology 15 (2024): 1445170, https://doi.org/10.3389/fphar.2024.1445170.
- 32A. Hernández Martínez, R. Madurga, N. García-Romero, and Á. Ayuso-Sacido, “Unravelling Glioblastoma Heterogeneity by Means of Single-Cell RNA Sequencing,” Cancer Letters 527 (2022): 66–79, https://doi.org/10.1016/j.canlet.2021.12.008.
- 33A. Gisina, I. Kholodenko, Y. Kim, M. Abakumov, A. Lupatov, and K. Yarygin, “Glioma Stem Cells: Novel Data Obtained by Single-Cell Sequencing,” IJMS 23, no. 22 (2022): 14224, https://doi.org/10.3390/ijms232214224.
- 34F. Chu, P. Wu, M. Mu, S. Hu, and C. Niu, “MGCG Regulates Glioblastoma Tumorigenicity via hnRNPK/ATG2A and Promotes Autophagy,” Cell Death & Disease 14, no. 7 (2023): 443, https://doi.org/10.1038/s41419-023-05959-x.
- 35D. Chai, L. Zhang, Y. Guan, J. Yuan, M. Li, and W. Wang, “Prognostic Value and Immunological Role of MORF4-Related Gene-Binding Protein in Human Cancers,” Frontiers in Cell and Developmental Biology 9. (2021): 703415, https://doi.org/10.3389/fcell.2021.703415.
- 36X. Chen, A. Gao, F. Zhang, et al., “ILT4 Inhibition Prevents TAM- and Dysfunctional T Cell-Mediated Immunosuppression and Enhances the Efficacy of Anti-PD-L1 Therapy in NSCLC With EGFR Activation,” Theranostics 11, no. 7 (2021): 3392–3416, https://doi.org/10.7150/thno.52435.
- 37J. S. Berek, X. Matias-Guiu, C. Creutzberg, et al., “FIGO Staging of Endometrial Cancer: 2023,” Journal of Gynecologic Oncology 34, no. 5 (2023): e85, https://doi.org/10.3802/jgo.2023.34.e85.
- 38Q. Song, R. Zhou, F. Shu, and W. Fu, “Cuproptosis Scoring System to Predict the Clinical Outcome and Immune Response in Bladder Cancer,” Frontiers in Immunology 13 (2022): 958368, https://doi.org/10.3389/fimmu.2022.958368.
- 39H. Su, Y. Hou, D. Zhu, et al., “Development of a Prognostic Risk Model Based on Oxidative Stress-Related Genes for Platinum-Resistant Ovarian Cancer Patients,” Practitioner 20, no. 1 (2025): 89–101, https://doi.org/10.2174/0115748928311077240424065832.
- 40Q. Zhang, X. Liu, Z. Chen, and S. Zhang, “Novel GIRlncRNA Signature for Predicting the Clinical Outcome and Therapeutic Response in NSCLC,” Frontiers in Pharmacology 13 (2022): 937531, https://doi.org/10.3389/fphar.2022.937531.
- 41Z. Ye, Y. Wang, R. Yuan, et al., “Vesicle-Mediated Transport-Related Genes Predict the Prognosis and Immune Microenvironment in Hepatocellular Carcinoma,” Journal of Cancer 15, no. 12 (2024): 3645–3662, https://doi.org/10.7150/jca.94902.
- 42J. Wu, X. Zhou, J. Ren, et al., “Glycosyltransferase-Related Prognostic and Diagnostic Biomarkers of Uterine Corpus Endometrial Carcinoma,” Computers in Biology and Medicine 163 (2023): 107164, https://doi.org/10.1016/j.compbiomed.2023.107164.
- 43J. Ji, J. Shen, Y. Xu, et al., “FBXO2 Targets Glycosylated SUN2 for Ubiquitination and Degradation to Promote Ovarian Cancer Development,” Cell Death & Disease 13, no. 5 (2022): 442, https://doi.org/10.1038/s41419-022-04892-9.
- 44F. Dall'Olio, M. Pucci, and N. Malagolini, “The Cancer-Associated Antigens Sialyl Lewisa/x and Sda: Two Opposite Faces of Terminal Glycosylation,” Cancers 13, no. 21 (2021): 5273, https://doi.org/10.3390/cancers13215273.
- 45J. Shu, J. Jiang, and G. Zhao, “Identification of Novel Gene Signature for Lung Adenocarcinoma by Machine Learning to Predict Immunotherapy and Prognosis,” Frontiers in Immunology 14 (2023): 1177847, https://doi.org/10.3389/fimmu.2023.1177847.
- 46D. Cong, Y. Zhao, W. Zhang, J. Li, and Y. Bai, “Applying Machine Learning Algorithms to Develop a Survival Prediction Model for Lung Adenocarcinoma Based on Genes Related to Fatty Acid Metabolism,” Frontiers in Pharmacology 14 (2023): 1260742, https://doi.org/10.3389/fphar.2023.1260742.
- 47S. Hänzelmann, R. Castelo, and J. Guinney, “GSVA: Gene Set Variation Analysis for Microarray and RNA-Seq Data,” BMC Bioinformatics 14, no. 1 (2013): 7, https://doi.org/10.1186/1471-2105-14-7.
- 48J. Friedman, T. Hastie, and R. Tibshirani, “Regularization Paths for Generalized Linear Models via Coordinate Descent,” Journal of Statistical Software 33, no. 1 (2010): 1–22.
- 49H. Fan, Q. Ni, Y. Fan, Z. Ma, and Y. Li, “C-Type Lectin Domain Family 5, Member A (CLEC5A, MDL-1) Promotes Brain Glioblastoma Tumorigenesis by Regulating PI3K/Akt Signalling,” Cell Proliferation 52, no. 3 (2019): e12584, https://doi.org/10.1111/cpr.12584.
- 50V. Chérouvrier Hansson, F. Cheng, G. Georgolopoulos, and K. Mani, “Dichotomous Effects of Glypican-4 on Cancer Progression and Its Crosstalk With Oncogenes,” IJMS 25, no. 7 (2024): 3945, https://doi.org/10.3390/ijms25073945.
- 51D. Manou, P. Bouris, D. Kletsas, et al., “Serglycin Activates Pro-Tumorigenic Signaling and Controls Glioblastoma Cell Stemness, Differentiation and Invasive Potential,” Matrix Biology Plus 6–7 (2020): 100033, https://doi.org/10.1016/j.mbplus.2020.100033.
- 52B. Mondal, V. Patil, S. D. Shwetha, et al., “Integrative Functional Genomic Analysis Identifies Epigenetically Regulated Fibromodulin as an Essential Gene for Glioma Cell Migration,” Oncogene 36, no. 1 (2016): 71–83, https://doi.org/10.1038/onc.2016.176.
- 53K. Zeng, Y. Zeng, H. Zhan, et al., “SEC61G Assists EGFR -Amplified Glioblastoma to Evade Immune Elimination,” Proceedings of the National Academy of Sciences of the United States of America 120, no. 32 (2023): e2303400120, https://doi.org/10.1073/pnas.2303400120.
- 54S. GC, K. Tuy, L. Rickenbacker, et al., “α2,6 Sialylation Mediated by ST6GAL1 Promotes Glioblastoma Growth,” JCI Insight 7, no. 21 (2022): e158799, https://doi.org/10.1172/jci.insight.158799.
- 55A. Pace, F. Scirocchi, C. Napoletano, et al., “Glycan-Lectin Interactions as Novel Immunosuppression Drivers in Glioblastoma,” IJMS 23, no. 11 (2022): 6312, https://doi.org/10.3390/ijms23116312.
- 56E. Okon, M. Koval, A. Wawruszak, et al., “Emodin-8-O-Glucoside—Isolation and the Screening of the Anticancer Potential Against the Nervous System Tumors,” Molecules 28, no. 21 (2023): 7366, https://doi.org/10.3390/molecules28217366.
- 57J. Ariztia, K. Jouad, V. Jouan-Hureaux, et al., “Clickable C-Glycosyl Scaffold for the Development of a Dual Fluorescent and [18F]Fluorinated Cyanine-Containing Probe and Preliminary in Vitro/Vivo Evaluation by Fluorescence Imaging,” Pharmaceuticals 15, no. 12 (2022): 1490, https://doi.org/10.3390/ph15121490.
- 58F. Lehmann, H. Slanina, M. Roderfeld, et al., “A Novel Insertion in the Hepatitis B Virus Surface Protein Leading to Hyperglycosylation Causes Diagnostic and Immune Escape,” Viruses 15, no. 4 (2023): 838, https://doi.org/10.3390/v15040838.
- 59P. Wen, J. Chen, C. Zuo, X. Gao, M. Fujita, and G. Yang, “Proteome and Glycoproteome Analyses Reveal the Protein N-Linked Glycosylation Specificity of STT3A and STT3B,” Cells 11, no. 18 (2022): 2775, https://doi.org/10.3390/cells11182775.
- 60H. Winer, G. O. L. Rodrigues, J. A. Hixon, et al., “IL-7: Comprehensive Review,” Cytokine 160 (2022): 156049, https://doi.org/10.1016/j.cyto.2022.156049.
- 61M. Rossi, P. Altea-Manzano, M. Demicco, et al., “PHGDH Heterogeneity Potentiates Cancer Cell Dissemination and Metastasis,” Nature 605, no. 7911 (2022): 747–753, https://doi.org/10.1038/s41586-022-04758-2.
- 62R. Zhang, Y. Yang, W. Dong, et al., “D-Mannose Facilitates Immunotherapy and Radiotherapy of Triple-Negative Breast Cancer via Degradation of PD-L1,” Proceedings of the National Academy of Sciences of the United States of America 119, no. 8 (2022): e2114851119, https://doi.org/10.1073/pnas.2114851119.
